News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Shows The Peril Of Going All-In



7/28/2017 6:12:43 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
When a failed drug trial moves the market caps of three different pharma companies by an aggregate $20 billion, you know it's important.AstraZeneca PLC's big effort to gain ground in the red-hot market for immune-boosting cancer drugs -- a combination of its already approved Imfinzi and a second immune-oncology (IO) drug tremelimumab -- was revealed as a flop in treating lung cancer Thursday morning. This trial -- code-named "Mystic" -- was always something of a Hail Mary. But it was one Astra desperately needed to work.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES